These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 10579076)
21. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Lopes AD; Davis WL; Rosenstraus MJ; Uveges AJ; Gilman SC Cancer Res; 1990 Oct; 50(19):6423-9. PubMed ID: 1698122 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic applications of monoclonal antibodies to human cancer. Borowitz MJ; Stein RB Arch Pathol Lab Med; 1984 Feb; 108(2):101-5. PubMed ID: 6546490 [TBL] [Abstract][Full Text] [Related]
23. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Wolf P; Freudenberg N; Bühler P; Alt K; Schultze-Seemann W; Wetterauer U; Elsässer-Beile U Prostate; 2010 Apr; 70(5):562-9. PubMed ID: 19938014 [TBL] [Abstract][Full Text] [Related]
24. PSMA specific antibodies and their diagnostic and therapeutic use. Holmes EH Expert Opin Investig Drugs; 2001 Mar; 10(3):511-9. PubMed ID: 11227049 [TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody (F5) to human prostate antigen. Papsidero LD; Croghan GA; Wang MC; Kuriyama M; Johnson EA; Valenzuela LA; Chu TM Hybridoma; 1983; 2(2):139-47. PubMed ID: 6205972 [TBL] [Abstract][Full Text] [Related]
26. Immunologic markers and the diagnosis of prostatic cancer. Ban Y; Wang MC; Chu TM Urol Clin North Am; 1984 May; 11(2):269-76. PubMed ID: 6203206 [TBL] [Abstract][Full Text] [Related]
28. PR1--a monoclonal antibody that reacts with an antigen on the surface of normal and malignant prostate cells. Pastan I; Lovelace E; Rutherford AV; Kunwar S; Willingham MC; Peehl DM J Natl Cancer Inst; 1993 Jul; 85(14):1149-54. PubMed ID: 7686582 [TBL] [Abstract][Full Text] [Related]
29. Localization of a normal prostatic secretory product using the monoclonal antibody KR-P8. Raynor RH; Mohanakumar T; Moncure CW; Hazra TA J Urol; 1985 Aug; 134(2):384-7. PubMed ID: 2410635 [TBL] [Abstract][Full Text] [Related]
30. PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response. Zhu ZY; Zhong CP; Xu WF; Lin GM; Ye GQ; Ji YY; Sun B; Yeh M Cell Res; 1999 Dec; 9(4):271-80. PubMed ID: 10628836 [TBL] [Abstract][Full Text] [Related]
31. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914 [TBL] [Abstract][Full Text] [Related]
32. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer. Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607 [TBL] [Abstract][Full Text] [Related]
33. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413 [TBL] [Abstract][Full Text] [Related]
34. Lucy Wortham James Basic Research Award. Markers of prostatic carcinoma. Murphy GP Arch Surg; 1991 Nov; 126(11):1404-7. PubMed ID: 1720951 [TBL] [Abstract][Full Text] [Related]
35. Ratio of polyclonal-monoclonal prostate-specific antigen levels. Discrimination of nodal status in prostate tumors that produce low marker levels. Stephenson RA; Greskovich FJ; Fritsche HA; James BC Urol Clin North Am; 1991 Aug; 18(3):467-71. PubMed ID: 1715103 [TBL] [Abstract][Full Text] [Related]